Mahatma Gandhi Cancer Hospital and Research Institute Dr P. S. Bhattacharyya, MD Radiation Oncologist. Elekta Synergy CT Simulator Flexitron HDR.

Slides:



Advertisements
Similar presentations
CLINICAL TRIALS IN CERVICAL CANCER Cancer Institute (WIA) experience.
Advertisements

Vaginal Balloon Packing System
Endometrial Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
CLINICAL WORKSHOP Image-Guided Adaptive Brachytherapy for Gynaecology Hospital name Participants’ names and roles Vienna, November 2013.
Dr.Sandeep.M Junior resident Dr.Ajaykumar Prof & HOD.
Incorporating Cesium-131 Interstitial Implants into Daily Clinical Practice: How to Make Radiation appear exactly where you want. Jonathan Feddock, MD.
University of Wisconsin
21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.
Morbidity / Complications
Impact of imaging on newer radiation techniques in Gynaecological cancer.
Radiation Protection in Radiotherapy
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
Prostate Radiotherapy A-Z
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
CET Cancer Center Oakland California High Dose Rate (HDR) Brachytherapy Gynecological Cancer D. Jeffrey Demanes M.D
Post-menopausal bleeding PV Dr Nasira Sabiha Dawood.
Abstract No A Phase I/II Study of the Angiogenesis Inhibitor Sorafenib in Cervical Cancer Patients Treated with Radiotherapy Naz Chaudary A. Fyles,
Learn More At: Northwest Hospital Gamma Knife Center Dr. Sandra Vermeulen, M.D. Swedish Cancer Institute Northwest Hospital Gamma.
Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González.
Dosimetric Comparison based on Consensus Delineation of Clinical Target Volume for CT- and MR-Based Brachytherapy in Locally Advanced Cervical Cancer Akila.
Technological advances in Brachytherapy
Radiotherapy to the female pelvis
Routine Use of Intraoperative Ultrasound Guidance during Intracavitary Brachytherapy Applicator Placement in Cervical Cancer: the University of Alabama.
In the name of God Isfahan medical school Shahnaz Aram MD.
Conclusions HDR brachytherapy boost combined with moderate dose external beam irradiation resulted in a very high local control rate and few recurrences.
Endometrial Carcinoma
Region of Interest Analysis as a Tool for Exploring Adaptive IMRT Strategy for Cervix Cancer Patients Young-Bin Cho 1,2, Valerie Kelly 1, Karen Lim 1,2,
Prostate Support Group Dr Duncan McLaren Consultant Oncologist.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
TEMPLATE DESIGN © ONCOLOGICAL REFERRAL PATTERNS OF GYNAECOLOGICAL CANCER PATIENTS OVER 2010 – 2011 THE NEED FOR GYNAECOLOGIC.
PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.
Comparison of Toxicity Profiles Associated with Three High-Dose-Rate Brachytherapy Treatment Schedules for Favorable-Risk Prostate Cancer Maha Saada Jawad,
A cost minimization exercise. Dr. Judith Aaron*, Dr. Balurishna S, Dr. SunithaSusan Varghese, Dr. Jasmine P, Dr. Selvamani B.
Permanent Interstitial Implants Ideal strategy to curatively manage small volume gynecologic malignancies Can deliver high cumulative radiation dose to.
Urinary Tract System Bladder Cancer.
Robert Taylor MD, PhD, Alexander Whitley MD, PhD, Craig Baden MD, Javier Lopez-Araujo MD, Sui Shen PhD, O. Lee Burnett MD, Jennifer De Los Santos MD and.
Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,
Brachytherapy and GYN malignancy
By: Ryan Rodriguez. What is it?  Cervical cancer is when abnormal cells on the cervix grow out of control.
Optimization of Volumetric Modulated Arc Therapy (VMAT) Planning Strategy Using Ring-shaped ROI for Localized Prostate cancer Kentaro Ishii, Masako Hosono,
Invasive cervical cancer. Background Most common cancer of women in Africa, most common gynaecologic cancer, most common cancer of black and coloured.
IMPACT OF PHYSICAL DOSE RATE EFFECT ON THE LONG TERM RESULTS OF THE CF-252 BRACHYTHERAPY OF CERVIX CARCINOMA E. Janulionis; K.P.Valuckas; V.Atkocius; V.Samerdokiene.
Outcome of patients treated with Image Guided Brachytherapy for Locally Advanced Carcinoma of the Cervix at Royal Devon & Exeter Hospital Dr.
To investigate the acute toxicity of 3D conformal concurrent chemo RT (Keeping PTV Dmax
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Stereotactic Body Radiation Therapy for Early Stage Prostate Cancer: Outcomes from a Single Institution Study Stereotactic Body Radiation Therapy for Early.
Patient and Tumour Characteristics Median age 60 years (26-92) Karnofsky Status:median 90 (50-100) Histology:SCC: n=120 (83%) Tumor size: ≥ 5 cm: n=78.
Stereotactic Body Radiation Therapy: An Emerging Treatment Approach for Early Stage Prostate Cancer Stereotactic Body Radiation Therapy: An Emerging Treatment.
Conflicts of Interest Nil conflicts of interest..
PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma.
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Cervix Version Table of Content StagingStaging, Manuscript Taipei Veterans General.
Taipei Veterans General Hospital Practices Guidelines Oncology Cervical Cancer Version VGH Survival Data as of YYYY/MM/DD Proofing on 2010/MM/DD.
Taipei Veterans General Hospital Practices Guidelines Oncology Rectal Cancer Version
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy For CK, one can fractionate the therapy yet remain convenient and non-invasive for.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS.
Brachytherapy in Carcinoma Prostate
Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.
THREE OR FOUR FRACTIONS PER WEEK IN POSTOPERATIVE HIGH DOSE RATE BRACHYTHERAPY (HDRBT) FOR ENDOMETRIAL CARCINOMA (EC). Rovirosa A1, Vargas M1, Ascaso C2,
Zehra Nihal Dolgun, Ahmet Salih Altintas, Cihan Inan, Petek Balkanli
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Comparative Results of Vaginal Relapses and Toxicity of Three 192-Ir HDR brachytherapy (BT) Schedules in Postoperative Endometrial Carcinoma (EC). Rovirosa.
Institute of Oncology “Ion Chiricuță”, Cluj, Romania
Dr Gemma Eminowicz Consultant Clinical Oncologist, UCLH, London
Preoperative endorectal brachytherapy in the treatment of locally advanced rectal cancer: Rethinking neoadjuvant treatment  Matthew C. Biagioli, MD, MS,
Cone beam computed tomography-based monitoring and management of target and organ motion during external beam radiotherapy in cervical cancer  Nina Boje.
Iris Metastasis from Small-Cell Lung Cancer
Volumetric and dosimetric comparison of two delineation guidelines for the radiation treatment of laryngeal squamous cell carcinoma  C. Bondue, S. Racadot,
Presentation transcript:

Mahatma Gandhi Cancer Hospital and Research Institute Dr P. S. Bhattacharyya, MD Radiation Oncologist. Elekta Synergy CT Simulator Flexitron HDR

Computed tomography assisted High Dose Rate Interstitial Brachytherapy in Gynaecologic Malignancies, with Inverse Planning Simulated Annealing ; An Institutional experience. Author-Dr P S Bhattacharyya, MD Co-author-Mr A C prabhu, Med. Phy.

Introduction Ca. Cx - 40% of all cases treated at MGCH EBRT + CDDP 40 mg/m ICRT / IBT GEC Estro guidelines for 3D ICRT MUPIT 2

Aims of the study To report IPSA based 3D HDR IBT in cancer Cervix and Vagina DVH analysis of CTV and OAR

Materials and Methods May 2012 to Dec 2012 Retrospective analysis 34 IBT applications in 17, Ca.Cx / Vagina patients Duration < 3 hrs Median 19 (17-23) needles used 8 – 9.5 Gy X 2 prescibed dose IPSA

Clinical and Histopathological features PRESENTATION Bleeding P/V White discharge Pelvic Pain NO. OF PATIENTS PERCENTAGE HPE Sq. Cell Ca. Adeno Ca SITE Intact Cervix Vault Vagina FIGO STAGE IIB IIIB IIIB with L/3 Vagina involved Total patients studied-17 Median age -56 Yrs.(18-68 yr)

Perineal Template Indications Bad Geometry 47% (08) Ca. Vault area 29% (05) Vaginal and para vaginal involvement 12% (02) Non negotiable cervical OS 06% (01) ICRT high dose to bladder 06% (01) Total No. of patients studied-17

Interstitial applicators Vienna CT-MRI Ring/ Ovoid Applicator Syed Neblett Template

MUPIT Applicator

BED and D EQ Equations BED Ext+HDR = (nd[1+(---)]) + (nd[1+(---)]) D EQ = BED Ext+HDR d d d ref 1+ ( ---- ) n = no. Of fractions d = dose per fraction in Gy a/b = alpha / beta, 10 for tumor, 3 for late effects BED=biologically equivalent dose D Eq= Equivalent dose (Gy) d ref= reference dose, 2 Gy a/b

IPSA Planning

CTV DVH Interpretations CTVRangeMedianBED 10 Tumor effects Dose Eq. Gy D – 8.49 Gy5.82 Gy D – 9.17 Gy8.42 Gy D – 9.60 Gy 8.74 Gy V10085 – %91.13% Median Prescribed dose- 8.8 Gy

OAR DVH Interpretation Bladder Volume cc Range Gy Median dose Gy BED 3 Late effects Dose Eq. Gy Rectal Volume cc Range Gy Median dose Gy BED 3 Late effects Dose Eq. Gy URINARY BLADDER RECTUM Median Prescribed Dose- 8.8 Gy

IPSA isodose distribution

Comparision of bladder dose 0.1 cc bladder dose 12 Gy with ICRT 0.1 cc bladder dose 8.1 Gy with IBT

Limitations of the study All the patients did not recieve 6 cycles of CDDP Total duration of treatment more than 8 weeks Applicator volume in CTV No subdivisions in CTV

Thank you